CTIS2023-506283-13-00
Recruiting
Phase 1
se of determination of drug levels to optimize pharmacotherapy of heart failure
Fakultni Nemocnice Ostrava0 sites100 target enrollmentAugust 10, 2023
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Chronic heart failure with reduced ejection fraction
- Sponsor
- Fakultni Nemocnice Ostrava
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •HFrEF with already established or newly started treatment with the listed medicinal products, Male and female patients over 18 years of age, Signed Informed Consent with participation in the study, Women of childbearing potential must have a negative serum human chorionic gonadotropin (hCG) result at the initial visit and use an acceptable method of contraception with a home control urine pregnancy test every 3 months throughout the duration of the study
Exclusion Criteria
- •Hypersensitivity to the medicinal substance or to any auxiliary substance, Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol \- sinus node dysfunction syndrome (including sinoatrial block), Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol \- severe hypotension (systolic blood pressure \<85 mmHg), Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol \- Prinzmetal angina, Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol \- untreated pheochromocytoma, Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol \- metabolic acidosis, Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol \- severe peripheral arterial circulation disorders, Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol \- concurrent intravenous treatment with verapamil or diltiazem, Additional exclusion criteria for patients using Spironolactone \- anuria, Additional exclusion criteria for patients using Spironolactone \- acute renal failure, Additional exclusion criteria for patients using Spironolactone \- severe renal impairment (estimated glomerular filtration rate \<10 ml/min), Pregnant and breastfeeding women, Additional exclusion criteria for patients using Spironolactone \- hyperkalemia \>5\.5 mmol/l, Additional exclusion criteria for patients using Spironolactone \- hyponatremia \<125 mmol/l, Additional exclusion criteria for patients using Spironolactone \- Addison's disease, Additional exclusion criteria for patients using Spironolactone \- concurrent use of eplerenone or other potassium\-sparing diuretics, Additional exclusion criteria for patients using Spironolactone \- porphyria, Additional exclusion criteria for patients using Sacubitril/Valsartan \- concomitant use with ACE inhibitors, Additional exclusion criteria for patients using Sacubitril/Valsartan \- angioedema related to previous ACE inhibitor treatment or a history of ARB treatment, Additional exclusion criteria for patients using Sacubitril/Valsartan \- hereditary or idiopathic angioedema, Additional exclusion criteria for patients using Sacubitril/Valsartan \- concomitant use with medicinal products containing Aliskiren in patients with diabetes mellitus or in patients with impaired renal function (eGFR \<60 ml/min/1\.73 m2\), Additional exclusion criteria for patients using Sacubitril/Valsartan \- severe liver dysfunction, biliary cirrhosis and cholestasis, Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol \- Unstable or decompensated heart failure belonging to the NYHA IV group according to the New York Heart Association classification, requiring intravenous inotropic support, Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol \- Clinically manifest liver dysfunction, Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol \- History of bronchospasm or asthma, Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol \- Severe obstructive airways disease, Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Meto
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A clinical pharmacology study to determine the pharmacokinetic , safety and tolerability profile and antiviral activity of multiple oral doses of A-831 in otherwise healthy male Hepatitis C carriers with compensated liver disease. - Clinical pharmacology study of A-831 in Hepatitis C carriersEUCTR2007-000328-42-GBArrow Therapeutics Ltd36
Not yet recruiting
Phase 4
Determination of Drug Levels for Pharmacotherapy of Heart FailureCardiovascular DiseasesHeart Failure With Reduced Ejection FractionNCT06035978University Hospital Ostrava100
Completed
Not Applicable
Pharmacists' review of medicine during admission to hospitalIn-hospital adverse drug eventsNot ApplicableOther complications of surgical and medical care, not elsewhere classifiedISRCTN08043800Region Zealand Hospital Pharmacy (Region Sjaelland Sygehusapoteket) (Denmark)648
Suspended
Not Applicable
Optimization of the pharmacological component using additive placeboeffects: Is it possible to enhance the psychological component during self-medication by disclosing information about the psychological componentsself-medication: participants using a specific analgesic (ibuprofen, paracetamol, aspirin) for pain relief self-medication: participants using a specific antihistamine (dimetindene, loratadine, cetirizine) for itch reliefDRKS00009506niversitätsklinikum Hamburg-Eppendorf Klinik und Poliklinik für Anästhesiologie108
Recruiting
Phase 3
Pharmacokinetics of Enteric Coated Mycophenolate Sodium in Lupus NephritisACTRN12611000798965Royal Brisbane32